Clinical Scorecard: Metformin Suppresses Growth of Small Intestinal Neuroendocrine Tumors in Animal Models

At a Glance

Key Highlights

• SI-NETs are the most common tumors of the small intestine with high metastatic potential.
• Metformin has shown promise in reducing tumor growth in SI-NET models.
• Combination therapies with metformin and other treatments like lanreotide or everolimus are being explored.
• MicroRNAs may serve as biomarkers for predicting treatment response in neuroendocrine tumors.
• The study utilized xenograft models to assess the effects of metformin on tumor growth.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of SI-NETs typically involves imaging and biopsy to confirm the presence of neuroendocrine cells.

Management

• Radical surgery is the only curative treatment for resectable SI-NETs.

Monitoring & Follow-up

• Tumor growth should be monitored using caliper measurements in preclinical studies.

Risks

• Metastatic disease is common at diagnosis, complicating treatment options.

Patient & Prescribing Data

Patients with small intestinal neuroendocrine tumors, especially those with metastases.

Metformin may be considered as part of a combination therapy approach in clinical trials.

Clinical Best Practices

• Consider the use of metformin in conjunction with standard treatments for SI-NETs in clinical trials.
• Monitor miRNA expression profiles to assess treatment response.

Related Resources & Content

• Study on Metformin and SI-NETs